SOURCE: MarketResearch.com

MarketResearch.com

May 24, 2010 11:11 ET

New Cancer Therapies Unseat Traditional Chemotherapy Regimens

ROCKVILLE, MD--(Marketwire - May 24, 2010) -  MarketResearch.com has announced the addition of Decision Resources 's new report "Special Report: Can New Therapies Unseat Traditional Chemotherapy Regimens in Acute Myelogenous Leukemia?" to their collection of Research & Development market reports. For more information, visit http://www.marketresearch.com/redirect.asp?progid=67618&productid=2663746

With optimal standard chemotherapy, 70% of acute myelogenous leukemia (AML) patients enter remission; however, only 20% live to become long-term survivors, and the average time of AML-patient survival is merely 18 months. Despite the development and success of newer cancer therapies (such as monoclonal antibodies [MAbs]) for the treatment of other cancers, therapies to treat AML have varied little over the past few decades. Although the AML pipeline is rich with new agents (44 confirmed agents in Phase I-III development), these drugs face a steep uphill battle in proving they are at least as safe and efficacious as the numerous, less expensive chemotherapeutic agents that currently dominate the AML market.

Questions Answered in This Report

  • An AML diagnosis is not always easy to determine initially because AML's symptoms can appear to be caused by other ailments. How is the diagnosis of AML ultimately made? What kinds of diagnostic tests are used, and what biological markers are indicative of an AML diagnosis?
  • Treatment of AML has changed very little in the past 30 years, with less expensive, generically available chemotherapies dominating the market. Why have no other agents challenged the commanding hold that chemotherapy has on the AML market? Is this positioning likely to change in the near term? What agents are in the clinical pipeline?
  • Elderly AML patients (aged 60 or older) face an even grimmer prognosis than their younger counterparts. What are the reasons for this poor prognosis? Is this poor prognosis a result of biological factors in this population? Is it compounded by comorbid conditions that occur primarily in the elderly?
  • Acute promyelocytic leukemia (APL), a subset of AML, is remarkably curable, in stark contrast to the other subsets of AML. How does APL differ from AML? Why is APL easier to cure than AML?

For more information, visit http://www.marketresearch.com/redirect.asp?progid=67618&productid=2663746

Contact Information